Ep. 384 - Back to School Special: The global FIH trials race

China has changed the global narrative on delivering early human clinical data, with a new bar for speed and efficiency. And now drug developers and policymakers around the world have gotten the message and know that this is no time for complacency. On a special edition of the BioCentury This Week podcast, BioCentury's analysts discuss why transformational reform for early clinical development will require rethinking the risk-control paradigm for first-in-human trials. It’s the subject of the 2026 Back to School issue, the 34th edition of an annual analysis that takes on one of the most pressing topics facing the biopharma industry.View full story: https://www.biocentury.com/article/660629#ClinicalTrials #FirstInHuman #DrugDevelopment #FDA #BiopharmaPolicy0:00 - Introduction6:40 - U.S.15:09 - Australia24:00 - China32:14 - EuropeTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text